Physician profile
Heather Gabrielle Bowers
NPI 1336376607
$93,588.08
in general payments reported to CMS, 2019-2025
14 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21K · 2022: $25K · 2023: $14K · 2024: $16K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $15K · Food and Beverage: $1,951 · Consulting Fee: $1,200 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,912.50 |
| Travel and Lodging | $14,561.40 |
| Food and Beverage | $1,951.10 |
| Consulting Fee | $1,200.00 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $88,276.30 | 2021-2025 | Jakafi, Jakafi |
| Pfizer INC. | $4,707.59 | 2021-2023 | |
| Seagen INC. | $325.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $45.67 | 2022-2023 | Onivyde, Somatuline Depot |
| Astellas Pharma US INC | $40.58 | 2023 | Padcev |
| Genzyme Corporation | $37.43 | 2025 | |
| Glaxosmithkline, LLC. | $24.23 | 2025 | Blenrep |
| Alnylam Pharmaceuticals INC. | $21.25 | 2024 | Onpattro |
| Novartis Pharmaceuticals Corporation | $20.90 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.68 | 2024 | Fruzaqla |
| Astrazeneca Pharmaceuticals Lp | $18.64 | 2024 | |
| Kyowa Kirin, INC. | $18.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.78 | 2024 | Opdualag |
| Genentech USA, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.